Cantor Fitzgerald Brokers Cut Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Biogen in a research note issued to investors on Thursday, February 13th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biotechnology company will post earnings of $16.13 per share for the year, down from their previous forecast of $17.04. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share.

Several other research analysts have also recently weighed in on the stock. Oppenheimer lowered their price target on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Truist Financial lowered their price target on shares of Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday. William Blair reissued an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. Barclays lowered their price target on shares of Biogen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 31st. Finally, Morgan Stanley lowered their price target on shares of Biogen from $192.00 to $157.00 and set an “equal weight” rating on the stock in a research report on Thursday. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $211.96.

Biogen Trading Up 3.8 %

Shares of BIIB stock opened at $138.45 on Friday. The company’s 50-day moving average price is $147.73 and its 200-day moving average price is $174.05. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The stock has a market cap of $20.17 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.65 and a beta of -0.08. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of BIIB. Grandfield & Dodd LLC increased its stake in shares of Biogen by 5.2% during the third quarter. Grandfield & Dodd LLC now owns 1,261 shares of the biotechnology company’s stock worth $244,000 after buying an additional 62 shares during the period. Quintet Private Bank Europe S.A. increased its stake in shares of Biogen by 9.7% during the third quarter. Quintet Private Bank Europe S.A. now owns 710 shares of the biotechnology company’s stock worth $138,000 after buying an additional 63 shares during the period. Signaturefd LLC increased its stake in shares of Biogen by 3.5% during the fourth quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company’s stock worth $320,000 after buying an additional 71 shares during the period. Quent Capital LLC increased its stake in shares of Biogen by 31.9% during the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock worth $46,000 after buying an additional 72 shares during the period. Finally, TD Private Client Wealth LLC increased its stake in shares of Biogen by 25.0% during the third quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company’s stock worth $75,000 after buying an additional 77 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.